Karyopharm Therapeutics Total Liabilities

As of the most recent data (June 2026), KPTI shows a total liabilities of $440M. That compares with $340M in the prior-year period — up 28.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KPTI's total liabilities is now $440M (was $340M) — a 28.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Karyopharm Therapeutics is outperforming or lagging.

Tracking KPTI's total liabilities over time shows whether Karyopharm Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $440M That compares with $340M in the prior-year period — up 28.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Karyopharm Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $440M) with ownership activity and broader fundamentals.

Karyopharm Therapeutics's total liabilities is $440M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.